Browse
Submit Data
Databases
API
Help

Dataset Information

305 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

MHC I peptides identification from various cell activation states

ABSTRACT: Not available

INSTRUMENT(S): instrument model

ORGANISM(S): Bos Taurus (bovine) Murine Leukemia Virus Brucella Abortus S19 Mus Musculus (mouse)

SUBMITTER: Attila Csordas

PROVIDER: PRD000479 | Pride | 2012-07-26

REPOSITORIES: Pride

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	PRIDE_Exp_Complete_Ac_18087.pride.mgf.gz	Mgf
	PRIDE_Exp_Complete_Ac_18087.pride.mztab.gz	Mztab
	PRIDE_Exp_Complete_Ac_18087.xml.gz	Xml
	PRIDE_Exp_Complete_Ac_18088.pride.mgf.gz	Mgf
	PRIDE_Exp_Complete_Ac_18088.pride.mztab.gz	Mztab

Items per page:

1 - 5 of 12

Similar Datasets

MHC II peptides identification from various cell activation states

Project description:Not available

2012-07-26 | PRD000480 | Pride

Mass Spectrometry-Based Identification of MHC-Associated Peptides.

Project description:Neoantigen-based immunotherapies promise to improve patient outcomes over the current standard of care. However, detecting these cancer-specific antigens is one of the significant challenges in the field of mass spectrometry. Even though the first sequencing of the immunopeptides was done decades ago, today there is still a diversity of the protocols used for neoantigen isolation from the cell surface. This heterogeneity makes it difficult to compare results between the laboratories and the studies. Isolation of the neoantigens from the cell surface is usually done by mild acid elution (MAE) or immunoprecipitation (IP) protocol. However, limited amounts of the neoantigens present on the cell surface impose a challenge and require instrumentation with enough sensitivity and accuracy for their detection. Detecting these neopeptides from small amounts of available patient tissue limits the scope of most of the studies to cell cultures. Here, we summarize protocols for the extraction and identification of the major histocompatibility complex (MHC) class I and II peptides. We aimed to evaluate existing methods in terms of the appropriateness of the isolation procedure, as well as instrumental parameters used for neoantigen detection. We also focus on the amount of the material used in the protocols as the critical factor to consider when analyzing neoantigens. Beyond experimental aspects, there are numerous readily available proteomics suits/tools applicable for neoantigen discovery; however, experimental validation is still necessary for neoantigen characterization.

| S-EPMC7139412 | biostudies-literature

Identification of cell wall and cytoplasmic proteins of Aspergillus fumigatus

Project description:Not available

2012-07-26 | PRD000510 | Pride

Straightforward ladder sequencing of peptides using a Lys-N metalloendopeptidase

Project description:Not available

2008-03-05 | PRD000046 | Pride

Sulfoxide derivatives of the methionyl peptides in human Jurkat T-lymphocytes

Project description:Not available

2006-02-08 | PRD000013 | Pride

Systematic identification of cancer-specific MHC-binding peptides with RAVEN.

Project description:Immunotherapy can revolutionize anti-cancer therapy if specific targets are available. Immunogenic peptides encoded by cancer-specific genes (CSGs) may enable targeted immunotherapy, even of oligo-mutated cancers, which lack neo-antigens generated by protein-coding missense mutations. Here, we describe an algorithm and user-friendly software named RAVEN (Rich Analysis of Variable gene Expressions in Numerous tissues) that automatizes the systematic and fast identification of CSG-encoded peptides highly affine to Major Histocompatibility Complexes (MHC) starting from transcriptome data. We applied RAVEN to a dataset assembled from 2,678 simultaneously normalized gene expression microarrays comprising 50 tumor entities, with a focus on oligo-mutated pediatric cancers, and 71 normal tissue types. RAVEN performed a transcriptome-wide scan in each cancer entity for gender-specific CSGs, and identified several established CSGs, but also many novel candidates potentially suitable for targeting multiple cancer types. The specific expression of the most promising CSGs was validated in cancer cell lines and in a comprehensive tissue-microarray. Subsequently, RAVEN identified likely immunogenic CSG-encoded peptides by predicting their affinity to MHCs and excluded sequence identity to abundantly expressed proteins by interrogating the UniProt protein-database. The predicted affinity of selected peptides was validated in T2-cell peptide-binding assays in which many showed binding-kinetics like a very immunogenic influenza control peptide. Collectively, we provide an exquisitely curated catalogue of cancer-specific and highly MHC-affine peptides across 50 cancer types, and a freely available software (https://github.com/JSGerke/RAVENsoftware) to easily apply our algorithm to any gene expression dataset. We anticipate that our peptide libraries and software constitute a rich resource to advance anti-cancer immunotherapy.

| S-EPMC6140548 | biostudies-literature

Identification of Human serum peptides

Project description:Identification of Human serum peptides Using ESI-QTOF

2010-07-30 | PRD000203 | Pride

Proteogenomics-based identification of the repertoire of human MHC class I-associated peptides

Project description:We have develop a proteogenomics-based approach for identification of human MHC class I-associated peptides, including those deriving from polymorphisms, mutations and non-canonical reading frames

2016-12-22 | GSE67174 | GEO

Identification of Ricin and Concanavalin A-binding Trypanosoma brucei Glycoproteins

Project description:Not available

2009-06-01 | PRD000808 | Pride

MS/MS identification of proteins from Emiliania huxleyi strain NZEH

Project description:Not available

2010-10-04 | PRD000804 | Pride